Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Navidea Biopharmaceuticals, Inc. (NAVB : OTC)

• Company Description    Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 2,471 shares Shares Outstanding: 100.08 (millions) Market Capitalization: $0.01 (millions) Beta: 1.71 52 Week High: $0.05 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -85.71% -86.32% 12 Week -83.33% -86.30% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4995 BRADENTON AVENUE SUITE 240 - DUBLIN,OH 43017 USA ph: 614-793-7500 fax: 614-793-7522 jkaufman@navidea.com http://www.navidea.com

• General Corporate Information    Officers Alexander L. Cappello - Chairman of the Board of Directors John K. Scott - Vice Chairman of the Board of Directors Erika L. Eves - Vice President; Finance Michael S. Rosol - Chief Medical Officer Amit Bhalla - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 63937X202 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 100.08 Most Recent Split Date: 4.00 (0.05:1) Beta: 1.71 Market Capitalization: $0.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - - 12/31/24 - - 09/30/24 - - Current Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Quick Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - - 09/30/24 - - Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©